222 related articles for article (PubMed ID: 31331038)
1. Epidermal Growth Factor is Effective in the Treatment of Diabetic Foot Ulcers: Meta-Analysis and Systematic Review.
Bui TQ; Bui QVP; Németh D; Hegyi P; Szakács Z; Rumbus Z; Tóth B; Emri G; Párniczky A; Sarlós P; Varga O
Int J Environ Res Public Health; 2019 Jul; 16(14):. PubMed ID: 31331038
[TBL] [Abstract][Full Text] [Related]
2. Topical Recombinant Human Epidermal Growth Factor for Diabetic Foot Ulcers: A Meta-Analysis of Randomized Controlled Clinical Trials.
Yang Q; Zhang Y; Yin H; Lu Y
Ann Vasc Surg; 2020 Jan; 62():442-451. PubMed ID: 31394225
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of recombinant human epidermal growth factor for diabetic foot ulcers: A systematic review and meta-analysis of randomised controlled trials.
Zhao DY; Su YN; Li YH; Yu TQ; Li J; Tu CQ
Int Wound J; 2020 Aug; 17(4):1062-1073. PubMed ID: 32343054
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Topical Recombinant Human Epidermal Growth Factor for Treatment of Diabetic Foot Ulcer: A Systematic Review and Meta-Analysis.
Yang S; Geng Z; Ma K; Sun X; Fu X
Int J Low Extrem Wounds; 2016 Jun; 15(2):120-5. PubMed ID: 27151755
[TBL] [Abstract][Full Text] [Related]
5. Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: A phase III multicenter, double-blind, randomized, placebo-controlled trial.
Park KH; Han SH; Hong JP; Han SK; Lee DH; Kim BS; Ahn JH; Lee JW
Diabetes Res Clin Pract; 2018 Aug; 142():335-344. PubMed ID: 29902542
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: a randomized double-blinded controlled trial.
Gomez-Villa R; Aguilar-Rebolledo F; Lozano-Platonoff A; Teran-Soto JM; Fabian-Victoriano MR; Kresch-Tronik NS; Garrido-Espíndola X; Garcia-Solis A; Bondani-Guasti A; Bierzwinsky-Sneider G; Contreras-Ruiz J
Wound Repair Regen; 2014; 22(4):497-503. PubMed ID: 25041620
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor outperforms placebo in the treatment of diabetic foot ulcer: a meta-analysis.
Rahim F; Yan X; Shah JA; Bibi N; Khan ZU; Nawaz S; Ming Y
F1000Res; 2022; 11():773. PubMed ID: 37867626
[No Abstract] [Full Text] [Related]
8. Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor.
Valenzuela-Silva CM; Tuero-Iglesias ÁD; García-Iglesias E; González-Díaz O; Del Río-Martín A; Yera Alos IB; Fernández-Montequín JI; López-Saura PA
Diabetes Care; 2013 Feb; 36(2):210-5. PubMed ID: 22966096
[TBL] [Abstract][Full Text] [Related]
9. Intralesional epidermal growth factor therapy in recalcitrant diabetic foot ulcers.
Özker E
J Wound Care; 2023 Apr; 32(Sup4):S14-S21. PubMed ID: 37029977
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of intralesional recombinant human epidermal growth factor in chronic diabetic foot ulcers.
Dumantepe M; Fazliogullari O; Seren M; Uyar I; Basar F
Growth Factors; 2015 Apr; 33(2):128-32. PubMed ID: 25856197
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of topical recombinant human platelet-derived growth factor for treatment of diabetic lower-extremity ulcers: Systematic review and meta-analysis.
Zhao XH; Gu HF; Xu ZR; Zhang Q; Lv XY; Zheng XJ; Yang YM
Metabolism; 2014 Oct; 63(10):1304-13. PubMed ID: 25060693
[TBL] [Abstract][Full Text] [Related]
12. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study.
Fernández-Montequín JI; Valenzuela-Silva CM; Díaz OG; Savigne W; Sancho-Soutelo N; Rivero-Fernández F; Sánchez-Penton P; Morejón-Vega L; Artaza-Sanz H; García-Herrera A; González-Benavides C; Hernández-Cañete CM; Vázquez-Proenza A; Berlanga-Acosta J; López-Saura PA;
Int Wound J; 2009 Dec; 6(6):432-43. PubMed ID: 20051095
[TBL] [Abstract][Full Text] [Related]
13. Human epidermal growth factor enhances healing of diabetic foot ulcers.
Tsang MW; Wong WK; Hung CS; Lai KM; Tang W; Cheung EY; Kam G; Leung L; Chan CW; Chu CM; Lam EK
Diabetes Care; 2003 Jun; 26(6):1856-61. PubMed ID: 12766123
[TBL] [Abstract][Full Text] [Related]
14. Silver based wound dressings and topical agents for treating diabetic foot ulcers.
Bergin SM; Wraight P
Cochrane Database Syst Rev; 2006 Jan; (1):CD005082. PubMed ID: 16437516
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of low-level light therapy for treatment of diabetic foot ulcer: A systematic review and meta-analysis of randomized controlled trials.
Li S; Wang C; Wang B; Liu L; Tang L; Liu D; Yang G; Zhang L
Diabetes Res Clin Pract; 2018 Sep; 143():215-224. PubMed ID: 30009935
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of hyaluronic acid for treating diabetic foot: a systematic review and meta-analysis.
Chen CP; Hung W; Lin SH
Dermatol Ther; 2014; 27(6):331-6. PubMed ID: 25039587
[TBL] [Abstract][Full Text] [Related]
17. Comparison of healing effectiveness of different debridement approaches for diabetic foot ulcers: a network meta-analysis of randomized controlled trials.
Ning P; Liu Y; Kang J; Cao H; Zhang J
Front Public Health; 2023; 11():1271706. PubMed ID: 38146472
[TBL] [Abstract][Full Text] [Related]
18. Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation.
Fernández-Montequín JI; Infante-Cristiá E; Valenzuela-Silva C; Franco-Pérez N; Savigne-Gutierrez W; Artaza-Sanz H; Morejón-Vega L; González-Benavides C; Eliseo-Musenden O; García-Iglesias E; Berlanga-Acosta J; Silva-Rodríguez R; Betancourt BY; López-Saura PA;
Int Wound J; 2007 Dec; 4(4):333-43. PubMed ID: 17953679
[TBL] [Abstract][Full Text] [Related]
19. Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers.
Yera-Alos IB; Alonso-Carbonell L; Valenzuela-Silva CM; Tuero-Iglesias AD; Moreira-Martínez M; Marrero-Rodríguez I; López-Mola E; López-Saura PA
BMC Pharmacol Toxicol; 2013 Sep; 14():44. PubMed ID: 24004460
[TBL] [Abstract][Full Text] [Related]
20. The Long-Term Outcomes Following the Application of Intralesional Epidermal Growth Factor in Patients With Diabetic Foot Ulcers.
Kahraman M; Misir A; Kizkapan TB; Ozcamdalli M; Uzun E; Mutlu M
J Foot Ankle Surg; 2019 Mar; 58(2):282-287. PubMed ID: 30612874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
